Manejo actual del glioblastoma multiforme

Contenido principal del artículo

Luís Rafael Moscote Salazar
Carlos Meneses García
Miguel Sáenz Amuruz
Pedro Penagos
Camilo Zubieta
Alfredo Romero

Resumen

El glioblastoma multiforme es el más común y más agresivo tumor del sistema nervioso central y se asocia con la mas baja sobrevida de todos los canceres en humanos. A pesar del tratamiento agresivo multimodal que comprende la resección quirúrgica, quimioterapia local y sistémica, la sobrevida media está en el rango de los 12 meses. Los pacientes con glioblastomas multiformes son considerados a recibir únicamente tratamiento de carácter paliativo sin ninguna esperanza de curación. La resección quirúrgica se basa en la premisa de la máxima posible que provea y alargue la sobrevida pero con el menor déficit neurológico. La radioterapia incrementa la duración de la sobrevida pero no es curativa y los agentes  quimioterapéuticos como la carmustina ofrecen, basado en  metanálisis, un discreto incremento en la sobrevida pero su uso todavía no se ha generalizado. Presentamos una revisión del estado actual del manejo del glioblastoma multiforme para el personal de ciencias de la salud. Rev.cienc. biomed.2010; 1 (2): 237 - 245

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Palabras clave:

Referencias (VER)

1. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, J Neurosurg, 2001;95:190–98.

2. Stewart LA, Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials, Lancet, 2002;359:1011–18

3. O’Reilly SM, Newlands ES, Glaser MG, et al., Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours, Eur J Cancer, 1993;29A:940–42

4. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide

5. followed by adjuvant temozolomide, J Clin Oncol, 2002;20:1375–82.

6. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T; ALA-Glioma Study Group.Neurosurgery. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.2008 Mar;62(3):564-76; discussion 564-76

7. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Pinto LW, Araújo MB, Vettore AL, Wernersbach L, Leite AC, Chimelli LM, Soares FA.

8. Virchows Arch. 2008 May;452(5):481-90.

9. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 2005;352:987–96.

10. Westphal M, Hilt DC, Bortey E, et al., A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro

11. Oncol, 2003;5:79–88.

12. Vredenburgh JJ, Desjardins A, Herndon JE II, et al., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, 2007;13:1253–9.

13. Maxwell JA, Johnson SP, Quinn JA, et al., Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma, Mol Cancer Ther, 2006;5:2531–9.

14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.

15. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical

16. trial. J Neurosurg. 1978;49:333-43.

17. Brada M, Thomas DG, Bleehan NM, Roberts JT, Senanayake F, Abram P, et al. Medical Research Council (MRC) randomized trial of adjuvant chemotherapy on high grade glioma (HGG)-BR05.

18. Proc Am Soc Clin Oncol. 1998;17: A1543.

19. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321-4.

20. Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino- 12,13- dihydro-13-(beta-D-glucopyranosyl) -5H-indolo [2,3-a]-pyrrolo[3,4-c]- carbazole-5,7(6H)- dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother

21. Pharmacol. 2001;48:250-4.

22. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997- 1003.

23. Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology. 1998;12:537- 43.

24. Williston Park.Russell D, Rubinstein L. Pathology of Tumors of the Central Nervous System. 5th ed. Baltimore, Williams & Wilkins, 1989, p. 1012.

25. Helseth A, Mark SJ. Neoplasms of the central nervous system in Norway: III. Epidemiological characteristics of intracranial gliomas according to histology. A.P.M.I.S. 1989; 97: 547–55.

26. Wong ML, Prawira A, Kaye AH, Hovens CM. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009 Sep;16(9):1119-30.

27. Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome

28. Project. J Neurosurg. 2003; 98(6): 1175-81.

29. Beany RP. Positron emission tomography in the study of hu-man tumors. Sem Nucl Med 1984;14:324-41.

30. Silverman DHS, Hoh CK, Seltzer MA, Schiepers C, Cuan GS Gambir SS, et al. Evaluating Tumor Biology and Oncological Disease with Positron Emission Tomography. Seminars in Ra- diation Oncology 1998;3:183-96.

31. Hawkins RA, Hoh C, Dahlbom M, Choi Y, Glaspy J, Tse N, et al. PET cancer evaluations with FDG. J Nucl Med 1991;32(8): 1555-8.

32. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncologic applications of positron emission tomo-graphy with fl uorine-18 fl uorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.

33. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37(7):1180-2.

34. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of Malignant Tumors: whole-body PET with fl uorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology 2001;220:54-62.

35. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feld- mann HJ, et al. O-(2-[18F] fl uoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27(5):542-9

36. Cairncross JG, Ueki K, Zlatescu MC, et al. Specifi c genetic predictors of chemo therapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–1479

37. Madajewicz S, Chowhan N, Tfayli A, Roque C,et al. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer. 2000 May 15;88(10):2350-6

38. Robins HI, Lassman AB, Khuntia D.Therapeutic advances in malignant glioma: current status and future prospects. Neuroimaging Clin N Am. 2009 Nov;19(4):647-56.

39. Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter methylation status can predict incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly

40. diagnosed glioblastoma. J Clin Oncol 26:2192- 2197, 2008

41. Taal W, Brandsma D, de Bruin HG, et al: Incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405- 4 1 0 , 2008

42. Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 50:624-628, 1979

43. Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999 Aug;46(2):183–8.

44. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of mo lecular alterations in glioblastomas for patients age < 50 years. Cancer 2005 Aug 15;104(4):825–32.